Zhejiang Shouxiangu Pharm Co (603896) - Total Assets
Based on the latest financial reports, Zhejiang Shouxiangu Pharm Co (603896) holds total assets worth CN¥3.22 Billion CNY (≈ $470.95 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check cash flow reinvestment rate of Zhejiang Shouxiangu Pharm Co to assess the company's total reinvestment commitment from operating cash flow.
Zhejiang Shouxiangu Pharm Co - Total Assets Trend (2012–2025)
This chart illustrates how Zhejiang Shouxiangu Pharm Co's total assets have evolved over time, based on quarterly financial data. Check 603896 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Zhejiang Shouxiangu Pharm Co - Asset Composition Analysis
Current Asset Composition (December 2025)
Zhejiang Shouxiangu Pharm Co's total assets of CN¥3.22 Billion consist of 44.8% current assets and 55.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 23.7% |
| Accounts Receivable | CN¥71.30 Million | 2.2% |
| Inventory | CN¥208.91 Million | 6.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥354.28 Million | 10.8% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Zhejiang Shouxiangu Pharm Co's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Zhejiang Shouxiangu Pharm Co (603896) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhejiang Shouxiangu Pharm Co's current assets represent 44.8% of total assets in 2025, a decrease from 53.0% in 2012.
- Cash Position: Cash and equivalents constituted 23.7% of total assets in 2025, up from 17.6% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 1.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 10.8% of total assets.
Zhejiang Shouxiangu Pharm Co Competitors by Total Assets
Key competitors of Zhejiang Shouxiangu Pharm Co based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871
|
China | CN¥3.25 Billion |
Zhejiang Shouxiangu Pharm Co - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.13 | 4.75 | 4.19 |
| Quick Ratio | 2.65 | 4.10 | 3.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥963.55 Million | CN¥1.14 Billion | CN¥742.80 Million |
Zhejiang Shouxiangu Pharm Co - Advanced Valuation Insights
This section examines the relationship between Zhejiang Shouxiangu Pharm Co's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.36 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | 4.8% |
| Total Assets | CN¥3.28 Billion |
| Market Capitalization | $423.54 Million USD |
Valuation Analysis
Below Book Valuation: The market values Zhejiang Shouxiangu Pharm Co's assets below their book value (0.13x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Zhejiang Shouxiangu Pharm Co's assets grew by 4.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Zhejiang Shouxiangu Pharm Co (2012–2025)
The table below shows the annual total assets of Zhejiang Shouxiangu Pharm Co from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥3.28 Billion ≈ $480.19 Million |
+4.80% |
| 2024-12-31 | CN¥3.13 Billion ≈ $458.19 Million |
-1.36% |
| 2023-12-31 | CN¥3.17 Billion ≈ $464.51 Million |
+11.14% |
| 2022-12-31 | CN¥2.86 Billion ≈ $417.95 Million |
+45.54% |
| 2021-12-31 | CN¥1.96 Billion ≈ $287.17 Million |
+15.47% |
| 2020-12-31 | CN¥1.70 Billion ≈ $248.70 Million |
+26.76% |
| 2019-12-31 | CN¥1.34 Billion ≈ $196.20 Million |
+12.53% |
| 2018-12-31 | CN¥1.19 Billion ≈ $174.36 Million |
+28.63% |
| 2017-12-31 | CN¥926.34 Million ≈ $135.55 Million |
+51.34% |
| 2016-12-31 | CN¥612.10 Million ≈ $89.57 Million |
+1.02% |
| 2015-12-31 | CN¥605.91 Million ≈ $88.66 Million |
+20.94% |
| 2014-12-31 | CN¥500.99 Million ≈ $73.31 Million |
+22.39% |
| 2013-12-31 | CN¥409.35 Million ≈ $59.90 Million |
+49.40% |
| 2012-12-31 | CN¥274.01 Million ≈ $40.10 Million |
-- |
About Zhejiang Shouxiangu Pharm Co
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. engages in the selection, cultivation, processing, and sale of medicinal materials in China. It offers Ganoderma lucidum spore powder and brand broken cell wall powder, as well as broken wall Ganoderma lucidum spore powder granules and powder tablets; Tiepi Fengdou granules; and Tiepi Fengdou Ganoderma lucidum extracts. The company offers its products … Read more